ObvioHealth and 1nHealth announce today a joint initiative to smooth the transition to hybrid and decentralized clinical research. The initiative focuses on supporting clinical trials that may be struggling due to suboptimal protocol design, imprecise recruitment strategies, maladapted technology options or ailing site teams. According to clinicaltrials.gov, there are about 1,600 suspended trials at present.
1nHealth conducts clinical trial recruitment using a unique combination of digital targeting and evidence-based creative that enabled it to deliver 100 percent of their 2021 DCT enrollment projects on time and on budget, a result that is virtually unheard of in the industry.
ObvioHealth is a leading global Virtual Research Organization (VRO) delivering end-to-end decentralized clinical trial solutions through its platform, smartphone app and seamless device integrations. The company boasts average study retention rates of 89 percent.
“It’s wonderful to see the industry rapidly adopting hybrid and virtual models, but this has sponsors confronting new recruitment challenges,” said Dan Brenner, Founder and CEO of 1nHealth. “We frequently hear from sponsors who can’t meet enrollment numbers and are increasingly brought on board to help get trials back on track.”
Both companies have leveraged their DCT and hybrid expertise to rescue trials that are failing to meet milestones. They recently collaborated on a women’s health study that considerably boosted enrollment and study completion rates, while reducing recruitment costs 10-fold.
